Aging-focused startup BioAge Labs, Inc. is gaining a key partner in metabolic disease for the upcoming Phase II trial of azelaprag for improving body composition in patients on GLP-1/incretin therapy for obesity. The company announced on 13 February the closing of a large series D venture capital funding round, which it will direct toward development of azelaprag in combination with Eli Lilly and Company’s Zepbound (tirzepatide) and other incretins, and a partnership with Lilly’s Chorus organization.
The financing will be used to investigate BioAge drug’s ability to promote weight loss and improve body composition in combination...